Age
Item
male or female, 18-85 years of age
boolean
C0001779 (UMLS CUI [1])
Blood pressure determination
Item
blood pressure in the range of 130 to 179/80 to 109 mmhg
boolean
C0005824 (UMLS CUI [1])
Angiotensin-Converting Enzyme Inhibitors | Angiotensin II receptor antagonist | Pharmaceutical Preparations Quantity Hypertensive disease
Item
currently using either an ace inhibitor or an arb alone or (an ace inhibitor or an arb and up to two other drugs for treatment of high blood pressure). (patients may be on both an ace inhibitor and arb, but would need to be taken off one.)
boolean
C0003015 (UMLS CUI [1])
C0521942 (UMLS CUI [2])
C0013227 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0020538 (UMLS CUI [3,3])
Pharmacotherapy Stable Hypertensive disease
Item
stable medication regimen for high blood pressure for at least one month prior to screening
boolean
C0013216 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0020538 (UMLS CUI [1,3])
Non-Insulin-Dependent Diabetes Mellitus Disease length | Diet therapy | Antidiabetics | Insulin Dose Stable
Item
stable type 2 diabetes mellitus for at least 3 months prior to screening that is controlled by any or all of the following: diet and antidiabetic medications that may include fixed-dose insulin
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0012159 (UMLS CUI [2])
C0935929 (UMLS CUI [3])
C0021641 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205360 (UMLS CUI [4,3])
Hemoglobin A1c measurement
Item
hgba1c 6.5 to 8.5% (this is measured at the screening visit)
boolean
C0474680 (UMLS CUI [1])
Adrenergic beta-Antagonists
Item
use of any beta blocker within one month prior to screening
boolean
C0001645 (UMLS CUI [1])
Clonidine
Item
use of clonidine within 3 months prior to screening
boolean
C0009014 (UMLS CUI [1])
Hyperthyroidism Laboratory Markers Abnormal
Item
diagnosis of hyperthyroidism as evidenced by abnormal lab markers
boolean
C0020550 (UMLS CUI [1,1])
C0162490 (UMLS CUI [1,2])
C0205161 (UMLS CUI [1,3])
Disease Requirement CORTICOSTEROIDS FOR SYSTEMIC USE Intermittent | Disease Requirement CORTICOSTEROIDS FOR SYSTEMIC USE chronic
Item
any disorder requiring the intermittent or chronic use of systemic corticosteroids
boolean
C0012634 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C3653708 (UMLS CUI [1,3])
C0205267 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C3653708 (UMLS CUI [2,3])
C0205191 (UMLS CUI [2,4])
Hyperthyroidism Determined by Laboratory Markers
Item
diagnosis of hyperthyroidism as determined by lab markers done at screening
boolean
C0020550 (UMLS CUI [1,1])
C0521095 (UMLS CUI [1,2])
C0162490 (UMLS CUI [1,3])
Liver diseases
Item
active liver disease as determined by lab markers
boolean
C0023895 (UMLS CUI [1])
Renal Insufficiency | Estimated Glomerular Filtration Rate
Item
kidney impairment; estimated gfr < 60 ml/min/1.73 m2
boolean
C1565489 (UMLS CUI [1])
C3811844 (UMLS CUI [2])
Myocardial Infarction | Cardiac Arrhythmia | Angina, Unstable | Coronary angioplasty | Coronary Artery Bypass Surgery | Cerebrovascular accident | Transient Ischemic Attack
Item
history of heart attack, clinically significant arrhythmia, unstable angina, coronary angioplasty/bypass surgery, stroke, or tia in 3 months prior to screening
boolean
C0027051 (UMLS CUI [1])
C0003811 (UMLS CUI [2])
C0002965 (UMLS CUI [3])
C0190211 (UMLS CUI [4])
C0010055 (UMLS CUI [5])
C0038454 (UMLS CUI [6])
C0007787 (UMLS CUI [7])
Chronic heart failure
Item
chronic heart failure
boolean
C0264716 (UMLS CUI [1])
Substance Use Disorders
Item
drug or alcohol abuse within 2 years prior to screening
boolean
C0038586 (UMLS CUI [1])
BETA BLOCKER ALLERGY | Hydrochlorothiazide allergy | Allergy to sulfonamides | Calcium-channel blocker allergy
Item
history of sensitivity to any beta blocker, hctz, sulfa drug, or calcium channel blocker
boolean
C0741466 (UMLS CUI [1])
C0571898 (UMLS CUI [2])
C0038757 (UMLS CUI [3])
C0570913 (UMLS CUI [4])
Study Subject Participation Status
Item
participation in another research study within 30 days prior to screening
boolean
C2348568 (UMLS CUI [1])